Is the CLEOPATRA Era Ending in HER2+ Metastatic Breast Cancer?

After more than a decade as the gold standard, the CLEOPATRA regimen faces its biggest challenge yet.

Drs. Mark Pegram and Fengting Yan discuss why emerging data from DESTINY-Breast09 may finally shift first-line HER2+ metastatic care.